Cover Image
市場調查報告書

H1N1亞型A型流感病毒感染:開發中產品分析

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 383707
出版日期 內容資訊 英文 209 Pages
訂單完成後即時交付
價格
Back to Top
H1N1亞型A型流感病毒感染:開發中產品分析 Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 209 Pages
簡介

H1N第一型感染疾病是同時被稱為豬流感的新型人類流感,由於傳染性病毒所引起。H1N第一型流感會影響鼻子,喉嚨,肺的呼吸道。同時這是傳染性疾病,感染者如果咳嗽和打噴嚏,會在空氣中散佈病毒。症候有咳嗽,發燒,喉嚨疼痛,鼻子堵塞,或是流鼻涕,身體酸痛,頭痛,疲勞感等。治療可用抗病毒藥等進行藥物治療。

本報告提供H1N1亞型A型流感病毒感染的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

H1N1亞型A型流感病毒感染 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/研究機關研究中的產品

治療藥的開發企業

治療藥的評估

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9686IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 7, 7, 1, 47, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 2, 1, 11 and 3 molecules, respectively.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Influenza A Virus, H1N1 Subtype Infections - Overview
  • Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
  • Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment
  • Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development
  • Influenza A Virus, H1N1 Subtype Infections - Drug Profiles
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects
  • Influenza A Virus, H1N1 Subtype Infections - Discontinued Products
  • Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Antigen Express Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by ContraFect Corp, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac AG, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by iBio Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by MedImmune LLC, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mucosis BV, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Novavax Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Touchlight Genetics Ltd, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova AB, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Pipeline by Visterra Inc, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top